| Name | Title | Contact Details |
|---|---|---|
Scott Strahler |
Chief Information Officer (CIO) North America | Profile |
Amy Shillingford |
Head of Information Technology | Profile |
Cynthia Pussinen |
Chief Technical Officer | Profile |
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.
Interleuken Genetics is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Howard County General Hospital Inc is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Hamner Institutes for Health Sciences is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.